QNASL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5605674 | TEVA BRANDED PHARM | Medicinal aerosol formulations |
Feb, 2014
(10 years ago) | |
| US5683677 | TEVA BRANDED PHARM | Medicinal aerosol formulations |
Nov, 2014
(9 years ago) | |
| US5776432 | TEVA BRANDED PHARM | Beclomethasone solution aerosol formulations |
Jul, 2015
(8 years ago) | |
| US7780038 | TEVA BRANDED PHARM | Dispensing apparatus with dosage counter |
Jan, 2027
(2 years from now) | |
| US10188811 | TEVA BRANDED PHARM | Nasal spray device |
Oct, 2031
(7 years from now) | |
Qnasl is owned by Teva Branded Pharm.
Qnasl contains Beclomethasone Dipropionate.
Qnasl has a total of 5 drug patents out of which 3 drug patents have expired.
Expired drug patents of Qnasl are:
- US5605674
- US5683677
- US5776432
Qnasl was authorised for market use on 17 December, 2014.
Qnasl is available in aerosol, metered;nasal dosage forms.
The generics of Qnasl are possible to be released after 21 October, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | Dec 17, 2017 |
| New Product(NP) | Mar 23, 2015 |
Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient
Market Authorisation Date: 17 December, 2014
Treatment: NA
Dosage: AEROSOL, METERED;NASAL
More Information on Dosage
QNASL family patents
